Who Owns Atrys Company?

Atrys Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Atrys Health?

Unveiling the ownership structure of the Atrys SWOT Analysis can unlock critical insights into its strategic trajectory and future potential. Understanding the key players behind Atrys Health is essential for investors, analysts, and anyone seeking to navigate the complexities of the healthcare technology market. This exploration of Atrys ownership delves into the company's evolution, from its inception to its current status as a publicly traded entity.

From its early days as a small startup to its current position, understanding who the Atrys shareholders are and how their influence shapes the company is crucial. The Atrys company's journey, marked by strategic shifts and significant market capitalization growth, offers a compelling case study in corporate governance and investment strategy. Examining the Atrys stock and its performance requires a deep dive into the company's ownership dynamics, including its major Atrys investors and their impact on the business.

Understanding the ownership structure of the Atrys company is crucial for investors and stakeholders. The company's journey began in 2007, evolving significantly over time. This chapter delves into the founders and early ownership dynamics of the healthcare provider, shedding light on the key players and initial investments that shaped its foundation.

The genesis of Atrys Health involved a merger in 2015 between Althia and eDiagnostic. This merger led to the adoption of the name Atrys Health, S.A. in May 2016. While specific details on the initial equity splits are not fully available, Dr. Santiago de Torres has been a key figure, serving as the executive president and chairman, significantly influencing the company's strategic direction.

Early backing from key investors played a vital role in the initial phases of Atrys Health. The company's early growth was supported by principal shareholders like Inveready, Grupo Onchena, and others. The Norwegian Government Pension Fund Global also made significant initial investments, showing confidence in the company's potential.

Founding and Early Structure

The company was formed in 2015 through a merger. Dr. Santiago de Torres is a key figure in the company's leadership.

Key Shareholders

Early investors included Inveready and Grupo Onchena. The Norwegian Government Pension Fund Global also invested early on.

Funding Rounds

The company secured a €640,000 grant in January 2018. A €9.2 million post-IPO equity round occurred in July 2020.

The early financial support and strategic partnerships were instrumental in Atrys Health's expansion and market positioning. The company's growth was fueled by funding rounds, including a grant of €640,000 in January 2018 from the Eurostars SME programme, and a €9.2 million post-IPO equity round in July 2020 with Aurica XXI as an investor. Understanding the initial ownership structure provides a foundation for analyzing the current Atrys ownership and Atrys shareholders. The Atrys company has evolved significantly since its inception, and its ownership structure continues to be a key aspect of its corporate strategy and investor relations.

Atrys SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of the Atrys company has evolved significantly since its initial public offering (IPO) on the BME Growth market in June 2016. Initially valued at €16 million, the company's market capitalization experienced substantial growth, reaching over €600 million by February 2022. This growth culminated in its transition to the main Spanish stock market, a strategic move designed to boost share liquidity and attract a wider array of both national and international investors. As of June 2025, the market capitalization of Atrys Health is approximately $238 million USD, reflecting the ongoing evolution of the company's valuation in the market.

Several capital increases and acquisitions have played a crucial role in shaping Atrys's ownership. In March 2022, a €16.5 million capital increase was approved to facilitate the acquisition of the Portuguese group Lenitudes S.P.G.S.A. Furthermore, a €219 million capital increase in May 2021 financed the takeover bid for ASPY Global Services S.A., which was overwhelmingly accepted by its shareholders. In June 2022, Atrys successfully completed a €72 million capital increase targeting qualified investors, including family offices and existing major shareholders, to fund the acquisition of Bienzobas. These strategic financial maneuvers have directly influenced Atrys's expansion into new markets and service areas.

The ownership of the Atrys company is largely held by private entities, which collectively control a significant portion of the shares. As of August 2024, private companies held a 39% stake, making them the largest ownership group. The top six shareholders together hold 53% of the company. Excelsior Times SL is the largest single shareholder, owning 25% of the outstanding shares. The Marketing Strategy of Atrys has been significantly influenced by these key shareholders and their strategic decisions.

Key Takeaways on Atrys Ownership

The ownership structure of Atrys has evolved significantly since its IPO, with a shift towards institutional and private investors.

• Private companies constitute the largest ownership group, holding a significant percentage of shares.
• Strategic capital increases and acquisitions have been pivotal in the company's growth and expansion.
• Major shareholders include Excelsior Times SL, Indumenta Pueri SL, and others.
• Institutional investors also hold a notable stake in the company.

Atrys PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at the Atrys company is the primary governing body, responsible for overseeing the management team and protecting the interests of the Atrys shareholders. As of May 2025, a significant leadership transition is underway. Santiago de Torres will move from executive chairman to a non-executive chairman role. Isabel Lozano, the current CEO, will become a non-executive director. Marian Isach is proposed to be appointed as an executive director at the Annual General Meeting on June 12, 2025, before assuming the CEO position. This succession plan, initiated in March 2024, highlights the company's focus on promoting internal talent and ensuring leadership continuity. This is crucial for Atrys healthcare as it navigates the evolving landscape of the healthcare industry.

The company's governance structure emphasizes best practices, including the establishment of control committees and adherence to legal requirements for listed companies. This focus on robust governance is essential for protecting the interests of Atrys investors and maintaining transparency. The changes in leadership and the emphasis on corporate governance are designed to support the company's long-term strategic goals and ensure sustainable growth.

The voting structure at Atrys generally follows a one-share-one-vote principle. General Meetings require at least 25% of subscribed capital with voting rights to be present for validity on the first call; the second call is valid regardless of attendance. Board members' voting rights collectively amounted to 3.77% as of February 2025. José Elías Navarro, representing Excelsior Times S.L., the largest shareholder, was appointed as a proprietary director by the Ordinary General Shareholders' Meeting on June 28, 2024, with a term extending until June 28, 2028. This shows a direct link between major shareholders and board representation, which allows for significant influence on decision-making, which is crucial for understanding the Atrys ownership structure.

Key Takeaways on Atrys' Governance

The Board of Directors is undergoing a strategic leadership transition to ensure continuity and promote internal talent. The voting structure is straightforward, with major shareholders having a direct influence on the board.

• Leadership transition with Santiago de Torres and Isabel Lozano changing roles.
• Marian Isach to become CEO after being appointed as executive director.
• Voting rights of board members totaled 3.77% as of February 2025.
• José Elías Navarro, representing the largest shareholder, is a proprietary director.
• For more details, you can read a Brief History of Atrys.

Atrys Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership profile of the Atrys Health has evolved through strategic initiatives. A key development is the leadership succession plan announced in March 2024, which will see Marian Isach take over as CEO and Santiago de Torres transition to a non-executive chairman role by June 2025. This internal promotion is designed to ensure continuity in the company's leadership.

Financially, Atrys Health saw a revenue increase of 5.5% in 2024, reaching €212.7 million, with adjusted EBITDA growing by 13.8% to €48.5 million. For the first quarter of 2025, revenues grew by 11.2% to €57.2 million. The company has also been active in mergers and acquisitions, completing 17 acquisitions since 2018, expanding its presence to seven countries and reaching a workforce of 2,000 professionals. In November 2023, Atrys announced an agreement to sell its remaining 75.01% stake in Conversia for €35 million, and in December 2023, the company issued convertible bonds totaling €13.3 million.

Industry trends often show increased institutional ownership and strategic investments in healthcare companies, and Atrys Health has seen continued support from institutional investors. The company's focus on organic and inorganic growth, alongside its leadership succession planning, suggests a commitment to sustained development within its existing public framework. This indicates a stable outlook for Atrys shareholders and the company's stock.

Atrys Ownership Overview

Atrys Health's ownership structure is primarily influenced by its status as a publicly traded company. Key aspects include institutional investors, and potentially, significant individual shareholders. The company’s strategic moves, like acquisitions and leadership changes, affect its ownership dynamics.

Recent Financial Performance

In 2024, Atrys Health reported revenues of €212.7 million, a 5.5% increase. Adjusted EBITDA grew by 13.8% to €48.5 million. The first quarter of 2025 showed a revenue increase of 11.2% to €57.2 million. These figures are crucial for understanding Atrys company financial reports and its market position.

Key Strategic Actions

Atrys has undertaken 17 acquisitions since 2018, expanding into seven countries. It sold its Conversia stake for €35 million in November 2023. The issuance of €13.3 million in convertible bonds in December 2023 is another significant development for Atrys investors.

Leadership Transition

Marian Isach will become CEO by June 2025, with Santiago de Torres transitioning to a non-executive chairman role. This leadership change is designed to provide stability and continuity. This is a key aspect of understanding who is the CEO of Atrys.

Atrys Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs